Skip to main content
. Author manuscript; available in PMC: 2022 Jan 20.
Published in final edited form as: Mol Pharm. 2021 Sep 15;18(10):3871–3881. doi: 10.1021/acs.molpharmaceut.1c00531

Figure 3.

Figure 3.

a) Uptake of [18F]6 in SJSA-1 tumor cells co-incubated with varying concentrations of the stapled peptide VIP116 (0 – 50 μM) was determined at 1 h post incubation, b) Binding affinity curve for [18F]6 on SJSA-1 cells. SJSA-1 cells were incubated with increasing concentrations of [18F]6, and the uptake was determined at 30 min post incubation. Nonspecific binding was assessed in parallel in cells that were exposed to RG7388 (50 μM). Data are shown as mean ± SD for triplicates. **p < 0.01, ***p < 0.0001 vs. no VIP116 co-incubation (0 μM).